Recent Advances in Research on Active Compounds Against Hepatic Fibrosis
- PMID: 37497688
- DOI: 10.2174/0929867331666230727102016
Recent Advances in Research on Active Compounds Against Hepatic Fibrosis
Abstract
Background: Almost all chronic liver diseases cause fibrosis, which can lead to cirrhosis and eventually liver cancer. Liver fibrosis is now considered to be a reversible pathophysiological process and suppression of fibrosis is necessary to prevent liver cancer. At present, no specific drugs have been found that have hepatic anti-fibrotic activity.
Objective: The research progress of anti-hepatic fibrosis compounds in recent ten years was reviewed to provide a reference for the design and development of anti-hepatic fibrosis drugs.
Methods: According to the structure of the compounds, they are divided into monocyclic compounds, fused-heterocyclic compounds, and acyclic compounds.
Results: In this article, the natural products and synthetic compounds with anti-fibrotic activity in recent ten years were reviewed, with emphasis on their pharmacological activity and structure-activity relationship (SAR).
Conclusion: Most of these compounds are natural active products and their derivatives, and there are few researches on synthetic compounds and SAR studies on natural product.
Keywords: HSC; Liver fibrosis; SAR; chronic liver diseases; cirrhosis; collagen I..
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Natural Products in Liver Fibrosis Management: A Five-year Review.Curr Med Chem. 2024;31(31):5061-5082. doi: 10.2174/0109298673288458240203064112. Curr Med Chem. 2024. PMID: 38362686 Review.
-
Application of Compounds with Anti-Cardiac Fibrosis Activity: A Review.Chem Biodivers. 2024 Dec;21(12):e202401078. doi: 10.1002/cbdv.202401078. Epub 2024 Oct 26. Chem Biodivers. 2024. PMID: 39223082 Review.
-
Recent advances in small molecule design strategies against hepatic fibrosis.Eur J Med Chem. 2025 Mar 15;286:117281. doi: 10.1016/j.ejmech.2025.117281. Epub 2025 Jan 17. Eur J Med Chem. 2025. PMID: 39854939 Review.
-
Research progress on the anti-hepatic fibrosis action and mechanism of natural products.Int Immunopharmacol. 2019 Oct;75:105765. doi: 10.1016/j.intimp.2019.105765. Epub 2019 Jul 20. Int Immunopharmacol. 2019. PMID: 31336335 Review.
-
Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis.Arch Pharm (Weinheim). 2024 Oct;357(10):e2400192. doi: 10.1002/ardp.202400192. Epub 2024 Jul 3. Arch Pharm (Weinheim). 2024. PMID: 38961537 Review.
Cited by
-
Comparative effectiveness of plant-derived compounds in keloid management: a review.Front Pharmacol. 2025 Jul 16;16:1576851. doi: 10.3389/fphar.2025.1576851. eCollection 2025. Front Pharmacol. 2025. PMID: 40741005 Free PMC article. Review.
References
-
- Sarin S.K.; Kumar M.; Eslam M.; George J.; Al Mahtab M.; Akbar S.M.F.; Jia J.; Tian Q.; Aggarwal R.; Muljono D.H.; Omata M.; Ooka Y.; Han K.H.; Lee H.W.; Jafri W.; Butt A.S.; Chong C.H.; Lim S.G.; Pwu R.F.; Chen D.S.; Liver diseases in the Asia-Pacific region: A lancet gastroenterology and hepatology commission. Lancet Gastroenterol Hepatol 2020,5(2),167-228 - DOI - PubMed
-
- Ebrahimi M.; Seyedi S.A.; Nabipoorashrafi S.A.; Rabizadeh S.; Sarzaeim M.; Yadegar A.; Mohammadi F.; Bahri R.A.; Pakravan P.; Shafiekhani P.; Nakhjavani M.; Esteghamati A.; Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis. Lipids Health Dis 2023,22(1),41 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous